COMMUNIQUÉS West-GlobeNewswire

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
10/11/2025
Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis [...]
Venus Concept Receives 510(k) for the Venus NOVA, Its Most Advanced Multi-Application Platform for Non-Invasive Body and Skin Treatments
10/11/2025
Venus NOVA is the first product clearance from the Company’s new R&D strategy TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global leader in medical aesthetic [...]
OneMedNet Delivers on Revenue Model Promise with Palantir-Powered RWD Subscriptions: Live Feeds & AI Search
10/11/2025
MINNEAPOLIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a leader in AI-empowered Real-World Data (RWD), today announced that it will demonstrate its next- [...]
Surgery Partners, Inc. Announces Third Quarter 2025 Results
10/11/2025
BRENTWOOD, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the [...]
Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
10/11/2025
Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE [...]
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
10/11/2025
WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding levels that led [...]
IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer
10/11/2025
Event being held today at 8:00 a.m. ET in New York City features presentations from Ovarian Cancer Key Opinion Leaders, Clinicians, Statistical Experts, and IMUNON executives Investors, stakeholders, analysts and those [...]
Bluejay Therapeutics’ Brelovitug (BJT-778) Monotherapy Achieved 100% Virologic Response and up to 82% Combined Endpoint of Virologic Response and ALT Normalization at Week 48 in Phase 2 Study in Chronic Hepatitis D (CHD)
10/11/2025
All brelovitug dose regimens studied were well tolerated Results will be presented at The Liver Meeting ® 2025 of AASLD Additional preclinical data presented on brelovitug mechanisms of action REDWOOD CITY, Calif., Nov [...]
Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships
10/11/2025
Company focused on advancing clinical milestones and strategic partnerships, with goal of positioning itself for future FDA clearance and product commercialization. Patient enrollment in SYMON-II clinical trial now [...]
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
10/11/2025
LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer [...]
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
10/11/2025
Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa weekly in [...]
Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors
10/11/2025
NEWTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic [...]
Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
10/11/2025
Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025 Expect to present interim analysis from approximately 25 six-month evaluable BCG- [...]
Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC
10/11/2025
SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, [...]
BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities
10/11/2025
KUALA LUMPUR, Malaysia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a biotechnology company advancing precision diagnostics and gene-based technologies across [...]
Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
10/11/2025
Completed enrollment with 530 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA) Completed $15 million registered direct offering and $125 million private placement with potential for up to an [...]
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025
10/11/2025
– The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically poor outcomes with AV fistula procedures – – The significantly longer [...]
Vaxxas Appoints Veteran Vaccine Leader to Board as Company Advances Needle-Free Vaccine Patch Towards Market
10/11/2025
Seasoned global pharmaceutical executive, Mr Brent MacGregor, joins Vaxxas Board to accelerate self-administered HD-MAP vaccines for global use; SPRIM Global Investment’s Co-Founder and Managing Partner, Mr Michael [...]
SpyGlass Pharma Announces Positive 36-Month First-in-Human and 3-Month Phase I/II Trial Results for Its Novel BIM-IOL System
10/11/2025
First-in-Human (FIH) Trial at 36 Months : 37% reduction in mean intraocular pressure (IOP) in evaluable patients across all dose groups with 95% of patients off all topical IOP-lowering drops 100% of evaluable patients [...]

Pages